Navigation Links
Tianyin Pharmaceutical Co., Inc. Announces Second Quarter 2008 Financial Results
Date:2/14/2008

1,746,999 1,042,043

CASH FLOWS FROM INVESTING ACTIVITIES

Acquisition of property and equipment (133,591) (50,719)

Additions to intangibles

-- (860,200)

Net Cash Used by Investing

Activities (133,591) (910,919)

CASH FLOWS FROM FINANCING ACTIVITIES

Repayment of short-term bank loans (801,540) --

Repayment of shareholder loans -- (13)

Repayment of long-term bank loans

(121,569) (40,123)

Net Cash Used by Financing

Activities (923,109) (40,136)

EFFECT OF FOREIGN CURRENCY TRANSLATION ON 44,728 18,970

CASH

NET INCREASE IN CASH AND CASH EQUIVALENTS 735,027 109,958

CASH AND CASH EQUIVALENTS - BEGINNING 624,390 740,780

CASH AND CASH EQUIVALENTS - ENDING $1,359,417 $850,738


'/>"/>
SOURCE Tianyin Pharmaceutical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Tianyin Pharmaceutical, Inc. to Host 2008 Second Quarter Earnings Conference Call on Thursday, February 14, 2008 at 4:15 p.m. EST
2. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
3. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Heritage and Ipca Enter Into Strategic Alliance for Generic Pharmaceutical Products
Post Your Comments:
*Name:
*Comment:
*Email: